Apparatus for implementing hyperthermia

Details Apparatus for implementing hyperthermia Apparatus for implementing hyperthermia

1999-05-25

2003-06-17

Sykes, Angela D. (Department: 3762)

Chemical apparatus and process disinfecting, deodorizing, preser

Blood treating device for transfusible blood

C604S004010, C604S006110, C604S006130, C607S106000

Reexamination Certificate

active

06579496

ABSTRACT:

FIELD OF THE INVENTION
The present invention relates to a specialized method for hyperthermia, including extracorporeal blood heating and sorbent-based detoxification, as an antiviral and antineoplasm protocol.
BACKGROUND OF THE INVENTION
Hyperthemia as a treatment of tumors has been carefully studied and applied since the 1960's. Prior to that time there were multiple reports of tumor regression coincident with febrile episodes. Subsequent analysis revealed that temperatures greater than 41° C. are ordinarily needed to induce tumor necrosis (tumor death). Although there are multiple methods of inducing hyperthermia by either direct skin contact or radiant heating, many physicians now favor an extracorporeal heat exchange (blood) circuit to raise patient temperatures. Patients may be maintained at 41.5° C. to 42° C. (rectal temperature) for three to four hours without severe cardiovascular compromise, although others report elevation of serum transaminases and bilirubin in patients kept at these temperatures for greater than 10 to 40 minutes. Instances of neurologic damage have been reported in association with serum hypophosphatemia, although no significant problems occurred once phosphate levels were maintained. Deaths have also been reported in two patients receiving hiyperthermia at 41.5° C. to 42° C. for 1-½ to 2 hours, presumably from massive liver tumor necrosis.
DcMoss, J. L. et al., “Hyperthermia in the Treatment of Cancer,”
The Journal of Extra-Corporeal Technology
, Volume 17, No. 1, pp. 37-43, 1985, explains that tumors are vulnerable to heal and that the goal of hyperthermic treatment therapy is to achieve cytotoxic temperatures in the tumor for a sufficient length of time without damaging the surrounding normal tissue. The rate at which blood flows through any given area of tissue. determines the amount of heat that may be carried away and therefore is a major determinant of the temperature rise in that tissue. In normal tissue, heat causes vasodilation. In a tumor, the microvasculature is made up of an overabundance of capillary beds which are unable to dilate. Blood flow through the area is thus more sluggish and commensurately unable to dissipate heat applied to the area. The inability to respond to heat by dilation, as normal vasculature would, also subjects the tumor to hypoxia, anaerobic metabolism and local acidosis, and these conditions in turn make the tumor tissue more vulnerable to thermal injury.
Other literature addressing the utility of hyperthermia in the treatment of malignancy includes: Sanchez, R., “Overview of Whole Body Hyperthermia Experience at American International Hospital,”
Consensus on Hyperthermia for the
1990s, Plenum Press, New York, pp. 203-208 (1990); Levin, R. D. et al., “Whole Body Hyperthermia Experience in Breast Cancer at American International Hospital,”
Consensus on Hyperthermia for the
1990s, Plenum Press, New York, pp. 387-391 (1990); Perez, C. A. et al., “Randomized Phase III Study Comparing Irradiation and Hyperthermia with Irradiation Alone in Superficial Measurable Tumors,”
Am. J. Clin. Oncol
., vol. 14, no. 2, pp. 133-141 (1991); and others.
Patents relating to methods for the extracorporeal treatment of blood for cancers, viruses and parasites include U.S. Pat. No. 2,886,771 to Vincent, No. 3,482,575 to Claff, No. 4,061,141 to Hyden, No. 4,191,182 to Popovich, No. 4,321,918 to Clark, No. 4,322,275 to Jain, No. 4,381,004 to Babb, No. 4,479,798 to Parks, No. 4,540,401 to Marten, No. 4,563,170 to Aigner, No. 4,576,143 to Clark and No. 4,692,188 to Troutner et al.
There were two reasons for exploring the use of hyperthermia as a treatment for viral-associated neoplasms when such work began a few years ago. First, hyperthermia was known to have caused tumor regression in both animal and in human sarcomas. Studies on the biochemical and physiologic effects of hyperthermia had shown that damage to microvasculature is important for tissue necrosis associated with heat. Second, the human lymphadenopathy associated virus was known to be heat-sensitive. McDougal et al. incubated lymphadenopathy associated virus at temperatures ranging from 37° to 60° C. and found the log kill followed first order kinetics. Thermal inactivation was decreased when the virus was in the lyophilized state compared to the liquid state (10 fold loss in LD
50
121 seconds at 56° C. for virus in media versus 32 minutes in lyophilized state). It was also found that lymphadenopathy virus was 40% inactivated after 30 minutes in a 42° waterbath, and 100% inactivated after the same time period at 56° C. Thus, hyperthermia can benefit patients suffering from viral infections in two ways. First, the hyperthermia kills malignant cells in the viral-associated neoplasms. Second, the hyperthermia directly inactivates the viruses themselves by denaturing them.
Studies have previously been completed in which whole body hyperthermia, achieved via extracorporeal circulation and thermoregulation, was used to treat Kaposi's Sarcoma associated with human immunodeficiency virus infection. While evaluation of the therapeutic effects of such treatment was the primary purpose of these studies, the simultaneous effects on HIV disease were evaluated by studying immunologic and virologic parameters of HIV infection as well as immunologic parameters related to Kaposi's Sarcoma.
In fact, the use of hyperthermia in acquired immunodeficiency syndrome patients with Kaposi's Sarcoma has received considerable public and media attention. The first two patients upon whom this procedure was performed were patients of the Atlanta pathologist Dr. Kenneth Alonso. Dr. Alonso initiated this experimental use of hyperthermia with Dr. William Logan, Jr., an Atlanta surgeon, as a pilot project to examine the possible use of this technique in the treatment of human immunodeficiency virus-associated diseases. Subsequently, Dr. Alonso requested that the National Institute of Allergy and Infectious Diseases (NIAID) evaluate the study techniques, results and patients.
As reported in O'Malley, S., “Hyperthermia: Perfusion's Answer . . . ?”,
Perfusion Life
, January 1991, pp. 6-13, a patient named Carl Crawford experienced a dramatic recovery from head-to-toe skin cancers after being treated with extracorporeal blood heating. (This case study was published in Logan, W. D. et al., “Case Report: Total Body Hyperthermia in the Treatment of Kaposi's Sarcoma . . . ,”
Med. Oncol. & Tumor Pharmacother
., vol. 8, no. 1, pp. 45-47 (1991).) Mr. Crawford had been diagnosed as having Kaposi's Sarcoma incident to human immunodeficiency virus infection, and had been told he had only two to four weeks left to live. Mr. Crawford was the first patient of Drs. Alonso and Logan, who together with perfusionist Joseph A. Guzman heated his blood to 42 degrees Centigrade which, the doctors said, killed the human immunodeficiency virus. Although NIAID discounted Mr. Crawford's recovery due to an alleged error in diagnosis—NIAID maintained that Mr. Crawford never had Kaposi's Sarcoma but had cat-scratch fever instead—six other doctors besides Drs. Alonso and Logan had diagnosed Mr. Crawford's skin lesions as Kaposi's Sarcoma and growing numbers of physicians are convinced that hyperthermia provides a proven antiviral protocol. For example, Dr. Robert S. Jenkins, Medical Director of the Immuno Suppressed Unit at Hollywood Community Hospital, believes that the hyperthermia was responsible for curing Mr. Crawford's Kaposi's Sarcoma lesions.
In a completely separate effort from Drs. Alonso and Logan, Dr. Shawn Hankins, a chiropractor in Port Angeles, Washington, has supported hyperthermia treatments since July, 1987 (as explained in the
Acquired Immunodeficiency Syndrome Treatment News
, Issue No. 104, Jun. 1, 1990, page 2). He points out that human immunodeficiency virus is heat sensitive and, in addition, hyperthermia can cause increased T-cell proliferation, phagocytosis, and increased production of antibodies and interferon. Observation

Affiliated with

Also associated with

Rating

Apparatus for implementing hyperthermia does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Apparatus for implementing hyperthermia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Apparatus for implementing hyperthermia will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3102727